Pharmaceutical company Dr. Reddy's Laboratories Ltd (BSE:500124) (NSE:DRREDDY) (NYSE:RDY) announced on Tuesday the availability of Chlordiazepoxide Hydrochloride and Clidinium Bromide Capsules USP, 5 mg/2.5 mg, in the US market.

Chlordiazepoxide Hydrochloride and Clidinium Bromide Capsules USP are a therapeutic equivalent generic version of Librax (chlordiazepoxide hydrochloride and clidinium bromide) approved by the US Food and Drug Administration (FDA). They are available in one strength of 5 mg/2.5 mg capsules in bottle count sizes of 100.

The product is indicated to help treat gastrointestinal disorders such as ulcers, irritable bowel syndrome and bowel infections.

According to IQVIA Health, the Librax brand and generic market had US sales of approximately USD105.9m MAT for the most recent 12 months ending in July 2021.